Dana Lukin
Gastroenterology · New York, NYNPI 1760640999
Payments from drug & device makers
Across 525 payments — averaging $1113.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$222K
- Johnson & Johnson$153K
- Pfizer$51K
- Takeda$37K
- Boehringer Ingelheim$36K
- F. Hoffmann-la Roche AG$27K
- plus $59K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 228 | $221,906 |
| Johnson & Johnson | 118 | $152,993 |
| Pfizer | 70 | $51,449 |
| Takeda | 5 | $36,933 |
| Boehringer Ingelheim | 3 | $35,875 |
| F. Hoffmann-la Roche AG | 3 | $26,565 |
| Hoffmann-la Roche Limited | 7 | $17,285 |
| E.r. Squibb & Sons, L.L.C. | 10 | $15,278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $12,650 |
| Janssen Global Services, LLC | 2 | $4,200 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $2,657 |
| Lilly USA, LLC | 5 | $2,560 |
| Bristol Myers Squibb | 26 | $1,918 |
| Eli Lilly | 2 | $922 |
| Fresenius Kabi USA, LLC | 3 | $633 |
| Boston Scientific | 1 | $127 |
| Celltrion USA Inc. | 3 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi | 2 | $55 |
| Amgen | 3 | $53 |
| Samsung HME America, Inc. | 1 | $50 |
| Madrigal Pharmaceuticals | 1 | $48 |
| Novo Nordisk | 2 | $39 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
| Janssen Scientific Affairs, LLC | 2 | $32 |
| Braintree Laboratories, Inc. | 1 | $26 |
| Evoke Pharma, Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $14 |
| Conmed Corporation | 1 | $12 |
How this compares
$584,606 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in New York
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Ira JacobsonNew York$1.8M
- James MarionNew York$1.7M
- Jean Frederick ColombelNew York$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.